GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-05. Numbers and descriptions here follow the published literature rather than marketing material.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
==== 2500–2599 ==== Trade Union Reform and Employment Rights Act 1993 (Commencement No. 2 and Transitional Provisions) Order 1993 (S.I. 1993/2503) Combined Probation Areas (Dorset) Order 1993 (S.I. 1993/2512) Teachers' (Superannuation and Compensation for Premature Retirement) (Scotland) Amendment Regulations 1993 (S.I. 1993/2513) Coal Industry Act 1992 (Commencement) Order 1993 (S.I. 1993/2514) Export of Goods (Control) (Amendment No. 5) Order 1993 (S.I. 1993/2515) Friendly Societies (Qualifications of Actuaries No.2) Regulations 1993 (S.I. 1993/2518) Friendly Societies (Amendment) Regulations 1993 (S.I. 1993/2519) Friendly Societies (Insurance Business No. 2) Regulations 1993 (S.I. 1993/2520) Friendly Societies (Authorisation No. 2) Regulations 1993 (S.I. 1993/2521) A11 Trunk Road (Roudham Heath to Attleborough Improvement and Slip Roads) Order 1993 (S.I. 1993/2524) A11 Trunk Road (Roudham Heath to Attleborough Improvement) (Detrunking) Order 1993 (S.I. 1993/2525) Protection of Wrecks (Designation No. 2) Order 1993 (S.I. 1993/2526) Police (Amendment) (No. 4) Regulations 1993 (S.I. 1993/2527) Police Cadets (Amendment) Regulations 1993 (S.I. 1993/2528) Fodder Plant Seeds (Amendment) Regulations 1993 (S.I. 1993/2529) Seeds (Registration, Licensing and Enforcement) (Amendment) Regulations 1993 (S.I. 1993/2530) Local Government Superannuation (Maternity Absence) Regulations 1993 (S.I. 1993/2531) Sea Fisheries Districts (Variation) Order 1993 (S.I. 1993/2532) Suppression of Terrorism Act 1978 (Application of Provisions) (India) Order 1993 (S.I.
=== Methods of assessment === An increase in prothrombin time, a coagulation assay, has been used as an indicator of vitamin K status, but it lacks sufficient sensitivity and specificity for this application. Serum phylloquinone is the most commonly used marker of vitamin K status. Concentrations <0.15 μg/L are indicative of deficiency. Disadvantages include exclusion of the other vitamin K vitamers and interference from recent dietary intake. Vitamin K is required for the gamma-carboxylation of specific glutamic acid residues within the Gla domain of the 17 vitamin K–dependent proteins. Thus, a rise in uncarboxylated versions of these proteins is an indirect but sensitive and specific marker for vitamin K deficiency.
When asked if Trump supported the Arab leaders' plan, a White House spokesman said that the current Arab plan does not address that Gaza is "currently uninhabitable" for Palestinians to live in to due to the amount of debris and unexploded ordnance, adding that "President Trump stands by his vision to rebuild Gaza free from Hamas. We look forward to further talks to bring peace and prosperity to the region." The US special envoy Steve Witkoff said the plan had "compelling features", was a good first step, and they needed additional discussions. The plan was also endorsed by the Organisation of Islamic Cooperation and several European countries. On 12 March, Arab foreign ministers confirmed continuous consultations on Egypt's plan with the US special envoy.
Alzheimer's disease is believed to occur when abnormal amounts of amyloid beta (Aβ), accumulating extracellularly as amyloid plaques, or tau proteins, accumulating intracellularly as neurofibrillary tangles, form in the brain, affecting neuronal functioning and connectivity, resulting in a progressive loss of brain function. This altered protein clearance ability is age-related, regulated by brain cholesterol, and associated with other neurodegenerative diseases. Deterministic causes for most Alzheimer's cases are still mostly unknown, except for 1–2% of cases where deterministic genetic differences have been identified. Predisposing causes (also known as "risk factors") such as hearing impairment and smoking are increasingly documented. Several unifying hypotheses attempt to explain underlying causes; the most predominant are the amyloid beta (Aβ) hypothesis, and the tau hypothesis.
It is a neuropsychiatric disorder, so besides the motor problems there is classically emotional lability (mood swings, or inappropriate mood), but also tics, anxiety, attention deficit etc. These can precede the motor symptoms. Non-neurologic manifestations of acute rheumatic fever may be present, namely carditis (up to 70% of cases, often subclinical, so echocardiography required), arthritis, erythema marginatum, and subcutaneous nodules.
Sources: en.wikipedia.org
MALAT1-associated small cytoplasmic RNA, also known as mascRNA, is a non-coding RNA found in the cytosol. This is a small RNA, roughly 53–61 nucleotides in length, that is processed from a much longer ncRNA called MALAT1 by an enzyme called RNase P. This RNA is expressed in many different human tissues, is highly conserved by evolution and shares a remarkable similarity to tRNA which is also produced by RNase P, yet this RNA is not aminoacylated in HeLa cells. The primary transcript, MALAT1 (metastasis associated lung adenocarcinoma transcript 1), appears to be upregulated in several malignant cancers. Another small RNA that is homologous to mascRNA, called menRNA, is processed from another long ncRNA called MEN beta. MALAT1 appears to be involved in the regulation of alternative splicing. MALAT1 interacts with SR proteins, influencing the distribution of these in nuclear speckle domains.
Eflornithine, sold under the brand name Ornidyl among others, is a medication used to treat African trypanosomiasis (sleeping sickness) and excessive hair growth on the face in women. Specifically it is used for the second stage of sleeping sickness caused by T. b. gambiense and may be used with nifurtimox. It is taken intravenously (injection into a vein) or topically. It is an ornithine decarboxylase inhibitor. Common side effects when applied as a cream include rash, redness, and burning. Side effects of the injectable form include bone marrow suppression, vomiting, and seizures. It is unclear if it is safe to use during pregnancy or breastfeeding. It is recommended typically for children over the age of 12. Eflornithine was developed in the 1970s and came into medical use in 1990. It is on the World Health Organization's List of Essential Medicines. In the United States the injectable form can be obtained from the US Centers for Disease Control and Prevention. In regions of the world where sleeping sickness is common, eflornithine is provided for free by the World Health Organization.
Wingstop's menu includes a wide range of chicken products such as bone-in and boneless wings, chicken tenders, and fried chicken sandwiches. There are 13 wing sauces, with some sauces available for limited periods as part of marketing efforts. Sides include fries, fried corn, and veggie sticks (carrots and/or celery). Sauces include ranch, blue cheese, honey mustard, and cheese sauce. The menu also includes chocolate brownies as a dessert option.
The German oculist Burchard Mauchart provided an early description in a 1748 doctoral dissertation of a case of keratoconus, which he called staphyloma diaphanum. However, it was not until 1854 that British physician John Nottingham (1801–1856) clearly described keratoconus and distinguished it from other ectasias of the cornea. Nottingham reported the cases of "conical cornea" that had come to his attention, and described several classic features of the disease, including polyopia, weakness of the cornea, and difficulty matching corrective lenses to the patient's vision. In 1859, British surgeon William Bowman used an ophthalmoscope (recently invented by Hermann von Helmholtz) to diagnose keratoconus, and described how to angle the instrument's mirror so as to best see the conical shape of the cornea. Bowman also attempted to restore vision by pulling on the iris with a fine hook inserted through the cornea and stretching the pupil into a vertical slit, like that of a cat. He reported that he had had a measure of success with the technique, restoring vision to an 18-year-old woman who had previously been unable to count fingers at a distance of 8 inches (20 cm). By 1869, when the pioneering Swiss ophthalmologist Johann Horner wrote a thesis entitled On the treatment of keratoconus, the disorder had acquired its current name.
Nicola Lucia B. Pohl is an American chemist who is the Joan & Marvin Carmack Chair at Indiana University Bloomington. She also serves as Associate Dean of Natural and Mathematical Sciences. Her research considers new approaches to make and analyse sugars. In 2020 she was elected a Fellow of the American Association for the Advancement of Science.
Sources: en.wikipedia.org
Opioid receptors are a group of inhibitory G protein-coupled receptors with opioids as ligands. The endogenous opioids are dynorphins, enkephalins, endorphins, endomorphins and nociceptin. Even though at the cellular level they are inhibitory, their activation is not always inhibitory: for example, activation of mu-opioid receptors activates (not inhibits) dopamine release, and activation of kappa-opioid receptors can lead to noradrenaline release, due to the location of these receptors on suppressor-cells releasing these neurotransmitters . The opioid receptors are ~40% identical to somatostatin receptors (SSTRs). Opioid receptors are distributed widely in the brain, in the spinal cord, on peripheral neurons, and digestive tract.
=== In biomedical science === In the biomedical sciences, PVDF is used in immunoblotting as an artificial membrane (usually with 0.22 or 0.45-micrometre pore sizes), on which proteins are transferred using electricity (see western blotting). PVDF is resistant to solvents and, therefore, these membranes can be easily stripped and reused to look at other proteins. PVDF membranes may be used in other biomedical applications as part of a membrane filtration device, often in the form of a syringe filter or wheel filter. The various properties of this material, such as heat resistance, resistance to chemical corrosion, and low protein binding properties, make this material valuable in the biomedical sciences for preparation of medications as a sterilizing filter, and as a filter to prepare samples for analytical techniques such as high-performance liquid chromatography (HPLC), where small amounts of particulate matter can damage sensitive and expensive equipment. PVDF transducers have the advantage of being dynamically more suitable for modal testing than semiconductor piezoresistive transducers and more compliant for structural integration than piezoceramic transducers. For those reasons, the use of PVDF active sensors is a keystone for the development of future structural-health monitoring methods, due to their low cost and compliance.
Director, Chuckling Goat. For services to Charity and to Innovation in Wales. Evelyn Mary Joy. Agent, Buckingham Conservative Association. For Political and Public Service. James Michael Keggen. Coxswain, Port St Mary Lifeboat Station, Royal National Lifeboat Institution. For voluntary services to Maritime Safety. Sharon Elaine Kelly. Project Manager, Royston Youth Action. For services to Young People. Lindsey Kemp. Officer, National Crime Agency. For services to Law Enforcement. Maurice Joseph Kennedy. Volunteer, Transport Training Board. For services to the Transport and Logistics Industries of Northern Ireland and Great Britain. Christine Anne Kenyon. Deputy Principal, The Manchester College, Greater Manchester. For services to Further Education. Michael Kettle. Explosives Officer, Metropolitan Police Service. For services to Bomb Disposal. Helen Morag Keys. Entrepreneur, Queen's University's Students' Union. For services to Entrepreneurship and Innovation in Farming. Jasdeep Hari Bhajan Singh Khalsa. Founder, The Sikher Project. For charitable services to the Sikh Community. Professor Saye Hock Khoo. Professor of Pharmacology and Therapeutics, University of Liverpool. For services to Infectious Diseases and Pharmacology. Virginia Kiddle. Officer, National Crime Agency. For services to Law Enforcement. Amy Kilby. UK Representative, International Project Management Organisation. For services to Military Communications. James Kilpatrick. Chair, RVH Liver Support Group. For services to People with Liver Disease and their Carers in Northern Ireland. Charline Zephoria King.
In February 2015, Labcorp acquired Covance for $6.1 billion. In October 2015, Labcorp acquired Safe Foods International Holdings and its two operating companies, International Food Network and The National Food Laboratory, expanding its capabilities in food and beverage product-development and product-integrity. In March 2016, Labcorp acquired Pathology Inc., a provider of reproductive donor testing as well as anatomic, molecular and digital pathology services focused on women's health. In September 2016, Labcorp acquired Sequenom for $371 million including debt, expanding its operations in Europe and Asia. In October 2016, Labcorp acquired ClearPath Diagnostics, a provider of laboratory diagnostic services in the Northeastern United States, from Shore Capital Partners. In May 2017, Labcorp acquired Pathology Associates Medical Laboratories from Providence Health & Services and Catholic Health Initiatives. In September 2017, Labcorp acquired Chiltern, a contract research organization (CRO), for $1.2 billion, and contributed it to Covance. In 2019, Labcorp acquired Wellness Corporate Solutions, a workplace wellness company.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.